Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review

• Published in: Curēus (Palo Alto, CA) Vol. 14; no. 11; p. e31570
• Main Authors: Dighriri, Ibrahim M, Alrabghi, Khawlah K, Sulaiman, Dilveen M, Alruwaili, Abdulrahman M, Alanazi, Nader S, Al-Sadiq, Al-Maha A, Hadadi, Amal M, Sahli, Bushra Y, Qasem, Basil A, Alotaibi, Manal T, Asiri, Taif T, Majrashi, Salman M, Alotibia, Noura T, Alhamyani, Afnan T, Alharbi, Amjad A
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 16-11-2022; Cureus
• Subjects: Anemia; Bias; Blood diseases; Drug dosages; Hematology; Hemoglobin; Iron; Pharmacokinetics; Public Health; Systematic review; Therapeutics; luspatercept; safety; efficacy; β-thalassemia; reblozyl
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.31570

β-thalassemia is characterized by the faulty generation of hemoglobin resulting in an elevated α/β globin ratio; this led to several patients needing red blood cell (RBC) transfusions for the rest of their lives. Luspatercept is an erythroid maturation test for treating various types of anemia, including β-thalassemia. It inhibits the Smad2/3 cascade and treats β-thalassemia by downregulating the transforming growth factor-beta (TGF-β) pathway. Luspatercept was evaluated in randomized controlled trials (RCTs). However, there is still limited data. Therefore, the study aims to review the current literature to assess the efficacy of luspatercept in cure β-thalassemia and its safety. From 2015 to 2022, searches were undertaken in PubMed, Google Scholar, and Cochrane. Only RCTs published in English were eligible for inclusion. The Cochrane Collaboration tool for bias assessment was used to analyze the quality of the publications. Our search strategy revealed 94 publications, of which 12 full-text papers were read and five were chosen for this review.All five trials included 1161 participants. Of whom, 153 (13.18%) entered phase 2, and 1008 (86.82%) entered phase 3. Two articles included 153 participants, of whom 70 (45.75%) were transfusion-dependent beta-thalassemia (TD) and 83 (54.25%) were non-transfusion-dependent beta-thalassemia (NTD) of phase 2. Three articles included 1008 participants, of whom 672 (66.67%) were given luspatercept and 336 (33.33%) were given a placebo. All participants in RCTs were 18 years of age or older. In phase 2, 0.2 to 1.25 mg/kg of luspatercept was given, and in phase 3, 1.0 to 1.25 mg/kg of luspatercept was given once every three weeks. In beta-thalassemia patients, luspatercept was more effective than a placebo and well tolerated. The high dose has shown promising results in the erythroid response, measured by a drop in blood transfusions or an average rise in hemoglobin levels. Luspatercept might make patients less likely to need RBC transfusions, improve their clinical results, and improve their quality of life. Adverse events were hyperuricemia, arthralgia, dizziness, influenza hypertension, and bone pain, but they were manageable.